462 related articles for article (PubMed ID: 14666736)
1. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G
Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736
[TBL] [Abstract][Full Text] [Related]
2. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Fukushima T; Yamamoto M; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 1998; 18(5D):3965-70. PubMed ID: 9854511
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
[TBL] [Abstract][Full Text] [Related]
4. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Ikeda K; Soma G; Fukushima T
Anticancer Res; 2002; 22(4):2447-53. PubMed ID: 12174942
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma.
Yamamoto M; Iwaasa M; Nonaka M; Tsugu H; Nabeshima K; Fukushima T
Anticancer Res; 2005; 25(6A):3715-23. PubMed ID: 16302731
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of the expression of endothelial-monocyte activating polypeptide II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Ueno Y; Hayashi S; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(6A):4081-6. PubMed ID: 11131676
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma.
Oshiro S; Tsugu H; Komatsu F; Ohnishi H; Ueno Y; Sakamoto S; Fukushima T; Soma G
Anticancer Res; 2006; 26(6A):4027-32. PubMed ID: 17195453
[TBL] [Abstract][Full Text] [Related]
8. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
Beauchesne PD; Taillandier L; Bernier V; Carnin C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
[TBL] [Abstract][Full Text] [Related]
9. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
10. Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas.
Nomiya T; Nemoto K; Kumabe T; Takai Y; Yamada S
BMC Cancer; 2008 Jan; 8():11. PubMed ID: 18199339
[TBL] [Abstract][Full Text] [Related]
11. [A clinical evaluation of combination therapy with radiation, MCNU, carboplatin and IFN-beta or with radiation, MCNU, carboplatin, etoposide and IFN-beta for malignant gliomas].
Mizumatsu S; Matsumoto K; Maeda Y; Tamiya T; Furuta T; Ohmoto T
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2055-60. PubMed ID: 9838907
[TBL] [Abstract][Full Text] [Related]
12. [Clinical trial of MCNU for malignant brain tumors].
Harada K; Okamoto H; Fujioka Y; Uozumi T; Kiya K; Kitaoka T; Goishi A; Sasaki U; Shima T; Inagawa T
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1423-31. PubMed ID: 2990350
[TBL] [Abstract][Full Text] [Related]
13. [Individualized therapy and outcomes of microsurgery, radiotherapy, and chemotherapy for astrocytoma].
Zhou WN; Chen ZP; You C; Mu YG; Sai K; Zhang JY; Zhang XH; Cheng JJ; Xu HC
Ai Zheng; 2004 Nov; 23(11 Suppl):1555-60. PubMed ID: 15566679
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of high-dose chemotherapy with autologous stem cell transplantation for patients with malignant astrocytomas.
Chen B; Ahmed T; Mannancheril A; Gruber M; Benzil DL
Cancer; 2004 May; 100(10):2201-7. PubMed ID: 15139065
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
Hallahan DE; Vokes EE; Rubin SJ; O'Brien S; Samuels B; Vijaykumar S; Kufe DW; Phillips R; Weichselbaum RR
Cancer J Sci Am; 1995; 1(3):204-9. PubMed ID: 9166477
[TBL] [Abstract][Full Text] [Related]
18. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
Yung WK; Kyritsis AP; Gleason MJ; Levin VA
Clin Cancer Res; 1996 Dec; 2(12):1931-5. PubMed ID: 9816151
[TBL] [Abstract][Full Text] [Related]
19. Pre-irradiation chemotherapy for newly diagnosed high grade astrocytoma.
Mathieu NT; Genet D; Labrousse F; Bouillet P; Denes SL; Martin J; Labourey JL; Venat L; Clavere P; Moreau JJ
Anticancer Res; 2004; 24(2C):1249-53. PubMed ID: 15154655
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
Rao RD; Krishnan S; Fitch TR; Schomberg PJ; Dinapoli RP; Nordstrom K; Scheithauer B; O'Fallon JR; Maurer MJ; Buckner JC
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):380-6. PubMed ID: 15667956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
